期刊文献+

多巴胺转运蛋白显像剂^(131)I-FP-β-CIT的临床前药理研究 被引量:2

Preclinical pharmacological studies of ^(131)I-FP-β-CIT as dopamine transporter imaging agent
在线阅读 下载PDF
导出
摘要 报道了用自制的131I-FP-β-CIT(N-(3’-氟丙基)-2β-羰甲氧基-3β-(4’-碘苯基)托烷)测定分配比,进行大鼠体内及脑内分布、兔血药清除动力学、大鼠脑放射自显影、猴显像和异常毒性等实验。结果显示:131I-FP-β-CIT脂溶性大,在pH为7.0和7.4时的分配比分别为15和28;药物能迅速进脑,并有较好的滞留(2 min时脑摄取为0.78%ID,2 h时为0.59%ID);脑内药物在纹状体中浓聚,1h时纹状体与小脑、额叶、海马的比值分别为5.23、2.15和3.10;纹状体的摄取能被β-CFT阻滞,表明药物与多巴胺转运蛋白(DAT)结合的亲和性和特异性较好;药物在兔血中清除迅速,血药浓度降至一半所需时间约为2 min;放射自显影显示出药物在纹状体区域的放射性浓聚,左右纹状体基本对称,纹状体与顶叶的比值为2.7;正常猴显像表明在注药后2 h时纹状体与颞叶、小脑的比值分别为5.4和3.0;异常毒性实验结果显示小鼠所耐受的剂量为人的750倍,表明药物非常安全。以上结果表明131I-FP-β-CIT与DAT有很好的亲和性与特异性,其体内性质适合显像,具有良好的临床应用前景。 The 13I-FP-β-CIT (2β-carbomethoxy-3β-(4-iodophenyl)tropane) was prepared by ourselves. Its partition coefficients were determined. Kinetics of blood clearance in rabbits, biodistribution in rats brains, toxicity test in mice as well as autoradiography in rat's brain, SPECT imaging in normal monkey's brain were studied. The partition coefficients were 15 and 28 at pH 7.0 and 7.4 respectively. The brain uptake in rats was rapid (0.78, 0.59 %ID/organ at 2 min, 2 h after injection respectively), the ratios of striatum/cerebellum, striatum /frontal cortex and striatum / hippocampus were 5.2,2.2 and 3.1 at 1 h in rat's brain. The uptake in striatum could be blocked by p-CFT, suggesting that 131I-FP-β-ClT binds to DAT specifically. The compound was rapidly cleared from rabbits' blood, taking only 2 min to reduce to half of the original concentration. The ratio of striatum/occipital cortex is 2.7 in autoradiography of rat's brain. l31l-FP-β-CIT concentrated in striatum in SPECT imaging in normal monkey. The ratio of striatum /cerebellum and striatum /occipital cortex were 5.4 and 6.0 respectively at 2 h. The test of toxicity showed that the dose received by mice was 750 times by human, proving the agent was safe. These results suggest that the compound is a good SPECT imaging agent for DAT.
出处 《核技术》 CAS CSCD 北大核心 2003年第11期858-862,共5页 Nuclear Techniques
基金 国家自然科学基金(39770230) 卫生部科研基金(98-1-326) 江苏省卫生厅重点科研基金(H2008)资助
关键词 帕金森病 显像剂 多巴胺转运蛋白 ^131I-FP-β-CIT 动物实验 Parkinson's disease, Imaging agents, Dopamine transporter, 131I- FP-β-CIT, Biodistribution
  • 相关文献

参考文献5

二级参考文献5

共引文献34

同被引文献17

  • 1蔡秀英,孔小明,费娜,孔岩,刘春风.药物干预对帕金森病大鼠行为的影响[J].苏州大学学报(医学版),2006,26(2):196-199. 被引量:1
  • 2Brooks DJ, Frey KA, Marek KL, et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinsoo's disease. Exp Neurol,2003, 184: S68-S79.
  • 3Jennings DJ, Seibyl J, Oakes D, et al. Clinical determinants of progressive dopamine transporter loss measured by β-CIT and SPECT. Mov Disord,2002, 17: 1104.
  • 4Brownell AL, Canales K, Chen YI, et al. Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson' s disease model.Neuro Image, 2003, 20: 1064-1075.
  • 5Schmidt N, Ferger B. Neurochemical findings in the MPTP model of Parkinson's disease. J Neurol Transm, 2001, 108: 1263-1282.
  • 6Robinson S, Freeman P, Moore C, et al. Acute and subchronic MPTP administration differentially affects striatal glutamate synaptic function.Exp Neurol, 2003, 180: 73-86.
  • 7Tanji H, Araki T, Nagasawa H, et al. Differential vulnerability of dopamine receptors in the mouse brain treated with MPTP. Brain Res,1999, 824: 224-231.
  • 8Bezard E, Dovero S, Bioulac B, et al. Effects of different schedules of MPTP administration on dopaminergic neurodegeneration in mice. Exp Neurol, 1997, 148: 288-292.
  • 9Tillerson JL, Caudle WM, Reveron ME, et al. Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson's disease. Neuroscience, 2003, 119: 899-911.
  • 10Gunther H, Hall H, Halldin C, et al. ^125I-β-CIT-FE and ^125I-β-CIT-FP are superior to ^125I-β-CIT for dopamine transporter visualization: autoradiographic evaluation in the human brain. Nucl Med Biol, 1997, 24: 629-634.

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部